載入...
Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer
The efficacy of the combination of a PARP inhibitor (PARPi) and an EZH2 inhibitor has been investigated in breast cancer cells with either BRCA1 mutation or BRCA2 mutation. However, earlier studies focused on the efficacy of this combination against BRCA-mutated but not BRCA-proficient breast cancer...
Na minha lista:
| 發表在: | FEBS J |
|---|---|
| 主要作者: | |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8096666/ https://ncbi.nlm.nih.gov/pubmed/33570247 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/febs.15730 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|